1. EMA-CHMP report, 2020: https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-assessment-report_en.pdf.
2. Use of intravenous iron and risk of anaphylaxis: a multinational observational post-authorisation safety study in Europe;Fortuny;Pharmacoepidemiol Drug Saf,2021
3. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-deficiency Anemia;Wolf;JAMA,2020
4. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia;Pollock;Expert Rev Hematol,2020
5. AEMPS report, 2020: https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2017/ni-muh_fv_08-2017-hierro_isomaltosido/.